"catalyst" three abstracts on mRNA-4157 (V940), an investigational mRNA individualized neoantigen therapy, have been accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 - June 4 in Chicago, IL. mRNA-4157 (V940) is being jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.
" catalyst" The FDA has informed Moderna that it is working to conclude the review by the end of May 2024. respiratory syncytial virus (RSV)
News 
Market Data 
Discover 
AI
